Roivant Sciences Ltd Ordinary Shares ROIV
News
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
Roivant Provides Update on Graves’ Disease Development Program
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
Pfizer shares downgraded as patent expirations loom
Roivant Sciences shares drop as lupus treatment misses trial goal
Trending: Roche to Buy Telavant From Roivant and Pfizer
Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion
Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion — Update
Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion Deal